When putting together your watch list, focus on stocks with an 80 or higher RS Rating. Ascendis Pharma ADR just cleared that benchmark with an upgrade from 78 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique rating tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains typically have an RS Rating of over 80 in the early stages of their moves.
Ascendis Pharma ADR is building a with a 180.78 entry. See if the stock can clear the breakout price in volume at least 40% above average.
The company reported 0% earnings growth in the latest quarterly report. Revenue increased 6%.
The company holds the No. 115 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte, TG Therapeutics and Gilead Sciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
